This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vertex Announces Positive Results From Viral Kinetic Study Of The Nucleotide Analogue ALS-2200 In People With Hepatitis C

Additional results from the study of ALS-2200 in people with hepatitis C are included in the following table:


Dose Group

Median BaselineHCV RNA(Log 10 IU/mL)(Min, Max)


Median Change FromBaseline After 3 Daysof Treatment(Log 10 IU/mL)(Min, Max)


Median Change FromBaseline After 7 Daysof Treatment(Log 10 IU/mL)(Min, Max)



6.30(5.70, 6.90)


0.13(-0.34, 1.22)


0.11(-0.28, 0.66)

15 mg


6.11(5.46, 7.00)


-0.49(-0.20, -0.99)


-0.97(-0.17, -1.59)

50 mg


6.19(5.73, 7.21)


-1.83(-1.41, -2.20)


-3.02(-2.21, -3.57)

100 mg


6.49(5.67, 7.00)


-2.60(-1.81, -3.78)


-3.95(-3.39, -4.51)

200 mg


6.18(5.66, 6.72)


-3.85(-2.87, -4.17)


-4.54(-3.81, -5.08)

*One patient had an HCV RNA level below the limit of detection (Roche COBAS Taqman HCV test, Version 2) during the study.

**Four patients had HCV RNA levels below the limit of quantification (<LOQ = < 25 IU/mL) during the study.

“The rapid advancement of ALS-2200 through this first viral kinetic study underscores the strength of our collaboration with Vertex and our shared commitment to develop new medicines for hepatitis C,” said Lawrence M. Blatt, Ph.D., Founder, President and Chief Executive Officer of Alios BioPharma. “We look forward to continued collaboration with Vertex and to the start of multiple Phase 2 studies of ALS-2200 later this year.”

2 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.49 -0.80%
FB $118.69 0.75%
GOOG $706.69 0.75%
TSLA $212.47 0.44%
YHOO $36.88 -0.16%


Chart of I:DJI
DOW 17,659.79 -0.92 -0.01%
S&P 500 2,046.33 -4.30 -0.21%
NASDAQ 4,701.82 -15.2740 -0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs